Tryton Medical Enters Into Strategic Agreement With Cardinal Health for Tryton's Side Branch Stent

October 28, 2016—Tryton Medical, Inc. and Cardinal Health announced that the companies have established a long-term strategic agreement for United States distribution of the Tryton side branch stent, pending regulatory approval. Tryton submitted a premarket approval application to the US Food and Drug Administration for the Tryton device in November 2015.

In Tryton’s announcement, Martin Leon, MD, commented, “In extensive clinical research, the Tryton side branch stent has demonstrated an ability to provide predictability and durability when treating coronary bifurcation lesions with significant side branches. This uniquely engineered stent has the potential to disrupt standard strategies for treating complex bifurcation lesions.” Dr. Leon is Director of the Center for Interventional Vascular Therapy at Columbia University Medical Center, New York-Presbyterian Hospital in New York, New York.

The company also announced that it is sponsoring a clinical symposium during TCT 2016, the 28th Transcatheter Cardiovascular Therapeutics scientific symposium in Washington, DC, on October 31. The symposium entitled, “Establishing the New Standard: Definitive Treatment for Complex Bifurcation Lesions,” will feature leading experts in the treatment of bifurcation.

The Tryton side branch stent is currently an investigational device in the United States. The device is commercially available in multiple countries within Europe, the Middle East, and Africa. It is not available in Japan.